Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 7 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Rezolute, Inc. | 119,675 | reported | 16 Dec 2025 | tx 16+271,675 |
| Ultragenyx Pharmaceutical Inc. | 18,703 | reported | 04 Oct 2019 | tx 5+106,000−1,297 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 16 Dec 2025 | PURCHASE | Rezolute, Inc. | 5,650 | 1.69 USD | |
| 19 Nov 2025 | GRANT_AWARD | Rezolute, Inc. | 21,000 | 0.00 USD | |
| 19 Nov 2025 | GRANT_AWARD | Rezolute, Inc. | 12,000 | 0.00 USD | deriv |
| 10 Jun 2025 | GRANT_AWARD | Rezolute, Inc. | 9,000 | 0.00 USD | |
| 10 Jun 2025 | GRANT_AWARD | Rezolute, Inc. | 5,000 | 0.00 USD | deriv |
| 31 Mar 2025 | PURCHASE | Rezolute, Inc. | 6,758 | 2.92 USD | |
| 18 Feb 2025 | PURCHASE | Rezolute, Inc. | 10,000 | 4.70 USD | |
| 16 Feb 2025 | GRANT_AWARD | Rezolute, Inc. | 25,500 | 0.00 USD | |
| 16 Feb 2025 | GRANT_AWARD | Rezolute, Inc. | 15,000 | 0.00 USD | deriv |
| 24 Sept 2024 | PURCHASE | Rezolute, Inc. | 4,259 | 4.70 USD | |
| 25 Jun 2024 | PURCHASE | Rezolute, Inc. | 4,815 | 4.15 USD | first after silence |
| 23 Jan 2024 | GRANT_AWARD | Rezolute, Inc. | 30,000 | 0.00 USD | deriv |
| 23 Jun 2022 | GRANT_AWARD | Rezolute, Inc. | 80,000 | 0.00 USD | deriv |
| 04 May 2022 | PURCHASE | Rezolute, Inc. | 25,000 | 3.80 USD | |
| 15 Oct 2021 | PURCHASE | Rezolute, Inc. | 7,693 | 6.50 USD | |
| 14 Jun 2021 | GRANT_AWARD | Rezolute, Inc. | 10,000 | 0.00 USD | deriv |
| 04 Oct 2019 | TAX_WITHHOLDING | Ultragenyx Pharmaceutical Inc. | 1,297 | 44.52 USD | |
| 01 Mar 2019 | GRANT_AWARD | Ultragenyx Pharmaceutical Inc. | 5,000 | 0.00 USD | |
| 01 Mar 2019 | GRANT_AWARD | Ultragenyx Pharmaceutical Inc. | 11,000 | 0.00 USD | deriv |
| 04 Oct 2018 | GRANT_AWARD | Ultragenyx Pharmaceutical Inc. | 15,000 | 0.00 USD | |
| 04 Oct 2018 | GRANT_AWARD | Ultragenyx Pharmaceutical Inc. | 75,000 | 0.00 USD | deriv |
1 purchase reported after at least 12 months of silence — most recent on 25 Jun 2024.